MGC Pharma Completes Safety Testing on its CBD Dermatological Products - CPNP Registration for European Sales Commenced
• MGC Pharmaceuticals has now commenced registration of its cannabidiol (CBD) based Dermatological treatment products for symptoms of acne, psoriasis and seborrhoea with the European Cosmetics Products Notification Portal (CPNP) • Upon grant of CPNP registration, the Company will be able to sell its CBD Dermatological skin care products throughout the European Union
• Registration follows the successful completion of its safety assessment, which included skin patch tests on 30 human volunteers for its cannabidiol (CBD) based products, targeted as a dermatological product for the relief and support of acne, psoriasis and seborrhoea skin conditions
• The skin patch test demonstrated no adverse dermatological symptoms on volunteers
• The Company will be shortly commencing 3-month Clinical tests on human volunteers in Slovenia to determine the efficacy of the products
MXC Price at posting:
4.6¢ Sentiment: Hold Disclosure: Held
